Trial Tentatively Backs DOACs After TAVR

(MedPage Today) -- In a departure from other transcatheter aortic valve replacement (TAVR, or TAVI) trials, direct oral anticoagulant (DOAC, or NOAC) therapy seemed to safely prevent subclinical leaflet thrombosis in ACASA-TAVI--but not convincingly...